New approaches to management of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia
This paper addresses the background of phosphodiesterase-5 inhibitors use in erectile dysfunction and lower urinary tract symptoms, as well as a special position which is held by tadalafil as an only drug from its class suitable for daily intake. Tadalafil pharmacodynamics and hypotheses concerning...
Main Authors: | S. I. Gamidov, T. V. Shatylko, N. G. Gasanov, N. A. Naumov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2019-10-01
|
Series: | Андрология и генитальная хирургия |
Subjects: | |
Online Access: | https://agx.abvpress.ru/jour/article/view/362 |
Similar Items
-
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
by: Kirill V. Kosilov, et al.
Published: (2020-06-01) -
Lower urinary tract symptoms and benign prostatic hyperplasia and their impact on quality of life
by: Antonio Carbone, et al.
Published: (2015-11-01) -
Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
by: Malik Suhail Ahmad, et al.
Published: (2022-01-01) -
The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
by: Seong Hyeon Yu, et al.
Published: (2022-08-01) -
Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis
by: Jianwei Cui, et al.
Published: (2021-10-01)